The latest price target for Baudax Bio Inc Ordinary Shares (OTC:BXRX) was reported by Noble Capital Markets on January 3, 2023. The analyst firm set a price target for $0.00 expecting BXRX to fall to within 12 months (a possible -100.00% downside). 0 analyst firms have reported ratings in the last year.

The latest analyst rating for Baudax Bio Inc Ordinary Shares (OTC:BXRX) was provided by Noble Capital Markets, and Baudax Bio Inc Ordinary Shares downgraded their market perform rating.

There is no last upgrade for Baudax Bio Inc Ordinary Shares

The last downgrade for Baudax Bio Inc Ordinary Shares happened on January 3, 2023 when Noble Capital Markets changed their price target from N/A to N/A for Baudax Bio Inc Ordinary Shares.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Baudax Bio Inc Ordinary Shares, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Baudax Bio Inc Ordinary Shares was filed on January 3, 2023 so you should expect the next rating to be made available sometime around January 3, 2024.

While ratings are subjective and will change, the latest Baudax Bio Inc Ordinary Shares (BXRX) rating was a downgraded with a price target of $0.00 to $0.00. The current price Baudax Bio Inc Ordinary Shares (BXRX) is trading at is $0.02, which is out of the analyst’s predicted range.